Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion
Executive Summary
Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.
You may also be interested in...
Second Long-Acting Antipsychotic Sampling Program Cleared By OIG Advisory Opinion
The second nearly identical advisory opinion that allows free samples of long-acting antipsychotics to certain hospitals without fear of kickback violations shows inefficiencies of the HHS OIG system for clarifying its fraud and abuse authorities.
Free Eye Drops Distribution To Mitigate Drug Side Effects Cleared By HHS OIG
Program relies on a third-party vendor managing a Risk Evaluation and Mitigation Strategy associated with the drug to facilitate delivery of eye drops to patients.
OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.